Pharmafile Logo

OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy

January 29, 2020 |  

Written by Gavin Jones, OPEN Health

The FDA has published their industry guidance on the topic of long term follow up (LTFU) post gene therapy. Please see a link to the full guidance below. In summary, they are stipulating that a good proportion of these therapies will require LTFU of up to fifteen years.

This presents significant challenge to manufacturers given that patients will, in that stretch of time, have multiple changes to their care settings and life circumstances. In addition to this, and if these therapies live up to their promise, treated ‘patients’ will potentially become chronically well and keen to disengage from their previous disease state and their healthcare professionals.

This is a significant challenge but achievable! We have already shared our experienced thinking on this topic and a link to our article is provided below. Our recommendations focus on putting the patient at the centre of a solution and wrapping a, digitally enabled, registry solution around thoughtful patient and healthcare professional engagement.

Please read our full thinking below:

http://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=5cf08b2f-f3d9-435a-8255-ef07542eb9a3&pnum=31

https://www.fda.gov/media/113768/download

Pink divider

Get in touch

If you would like to discuss further please contact our director of rare disease: gavinjones@openhealthgroup.com

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

OPEN Health announces a new team of experts will lead its HEOR & Market Access Scientific Office

OPEN Health, a global provider of consultancy, HEOR and market access, and scientific communications services, announced a new team of experts will lead its HEOR & Market Access Scientific Office.

OPEN Health Appoints Richard Jones as President for Evidence & Access

OPEN Health is pleased to announce the appointment of Richard Jones as President for Evidence & Access.

Drive, Discover, Dive_OPEN Health

Learn how to unlock the power of simplicity in complex omnichannel healthcare communications.

Novel Oncology Therapies Require Innovative Methods in Oncology Modeling

Innovative methods in oncology modeling are needed to demonstrate the value of many new cancer treatments, including immuno-oncologic therapies.

The CM Group rebrands to OPEN Health

Following its acquisition by OPEN Health in 2022, The CM Group, a US healthcare agency offering a suite of solutions to the biotech and pharma industry, has undergone extensive rebranding...

OPEN Health to acquire leading US-based life science strategy and advisory firm Acsel Health

OPEN Health to acquire leading US-based life science strategy and advisory firm Acsel Health

OPEN Health Appoints David P. King as Non-Executive Chairman and Paul Carter as Independent Board Member

OPEN Health has announced additions to its board of directors, appointing David P. King as non-executive Chairman and Paul Carter as an independent board member.

Steve Chick joins OPEN Health as Chief Growth Officer for Evidence & Access

OPEN Health is pleased to announce the appointment of Stephen J. Chick as Chief Growth Officer for OPEN Health Evidence & Access.

OPEN Health to acquire leading US medical communications platform The CM Group from NaviMed Capital

OPEN Health, a pre-eminent global provider of scientific communications and market access services, announced that it signed a binding agreement to acquire The CM Group, a leading US domestic medical...

How digital health is changing the relationship between patients and health providers | OPEN Health

The pandemic has forced pharmaceutical industry to look at digital in a new way - and it’s driving better health outcomes